Mathias Oelke

Mathias Oelke is the CSO of NexImmune. Dr. Oelke is a scientific co-founder of NexImmune and joined NexImmune in 2014. Dr. Oelke has more than 20 years of research experience in cancer immunotherapy and has a long-standing track record of developing methods for antigen-specific stimulation of T cells for therapeutic use. Prior to his promotion, he served as Senior Vice President, Preclinical Immunotherapy and Head of Cell Biology of NexImmune since 2017. Dr. Oelke has numerous peer-reviewed publications and is a co-inventor on more than 25 patents and patent applications describing NexImmune’s proprietary aAPC technology, with additional pending patent applications in related fields of cancer immunotherapy. Previously, he was a member of the faculty at the Johns Hopkins University for over 11 years. Dr. Oelke, who is a chemist by training, received his Ph.D. in Biology from University of Freiburg, where he first became interested in the critical role of antigen presenting cells and their use in immunotherapy.

Mathias Oelke is the Chief Scientific Officer at NexImmune, based in United States, North America. With a background in Biotechnology, Mathias Oelke has a rich history of leadership and innovation. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.